Biolexis Therapeutics, Inc. a clinical-stage AI-driven biopharmaceutical company, today announced it will present a late-breaking poster at the 2024 American Association of Immunologists (AAI), taking place May 3-7, 2024, in Chicago, IL.
AMERICAN FORK, Utah, May 1, 2024 /PRNewswire/ -- Biolexis Therapeutics, Inc. a clinical-stage AI-driven biopharmaceutical company, today announced it will present a late-breaking poster at the 2024 American Association of Immunologists (AAI), taking place May 3-7, 2024, in Chicago, IL. The conference brings together the top immunology experts for in-depth discussions exploring a wide array of topics, highlighting the latest groundbreaking discoveries in the field. Biolexis' scientific team will be presenting pre-clinical data demonstrating the efficacy of the company's novel PIM1-inhibitor, BLX-0631. AAI poster presentation details are below: Title: "Development of highly selective, potent, orally available PIM1 inhibitor BLX-0631 shows a therapeutics potential in Systemic Lupus Erythematosus (SLE) models" More information can be found on the AAI meeting website. About Biolexis Therapeutics, Inc. For more information, please visit www.biolexistx.com
SOURCE Biolexis Therapeutics Inc |